West Pharmaceutical Services, Inc. · NYSE (us_market)
Healthcare · Medical Instruments & Supplies · United States
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging products. This segment also provides drug containment solutions in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. This segment primarily serves pharmaceutical, diagnostic, and medical device companies. It sells and distributes its products through its sales force and distribution network, contract sales agents, and regional distributors. West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2025-11-04$286.94 RISE2026-03-12$231.09 PEAK2026-05-08$325.92 185d | -19.5% 128d | Missed | Missed | — | — | +41.0% 57d | Missed |
DROP2025-10-23$307.25 RISE2026-02-03$230.95 PEAK2026-04-23$309.70 182d | -24.8% 103d | Missed | Missed | — | — | +34.1% 79d | Missed |
DROP2025-01-22$347.87 RISE2025-04-08$190.39 PEAK2025-06-10$227.70 139d | -45.3% 76d | Missed | Missed | — | — | +19.6% 63d | Missed |
DROP2025-01-22$347.87 RISE2025-02-13$199.11 PEAK2025-03-18$234.47 55d | -42.8% 22d | Missed | Missed | — | — | +17.8% 33d | Missed |
DROP2023-08-29$412.41 RISE2024-01-03$338.27 PEAK2024-02-07$413.00 162d | -18.0% 127d | Missed | Missed | — | — | +22.1% 35d | Missed |
DROP2023-08-29$412.41 RISE2023-10-31$318.29 PEAK2024-01-29$370.50 153d | -22.8% 63d | Missed | Missed | — | — | +16.4% 90d | Missed |
DROP2022-08-03$343.65 RISE2022-11-03$209.34 PEAK2023-02-01$271.59 182d | -39.1% 92d | 2022-10-31 $230.10 | 2023-02-01 $271.59 | 70Quality on Sale | 59Quality on Sale | +29.7% 90d | +18.0% Held 93d |
DROP2022-04-07$420.45 RISE2022-06-14$280.61 PEAK2022-08-03$343.65 118d | -33.3% 68d | 2022-05-09 $296.82 | 2022-07-28 $339.92 | 60Quality on Sale | 44Watch | +22.5% 50d | +14.5% Held 80d |
DROP2021-12-31$469.01 RISE2022-05-11$290.80 PEAK2022-08-03$343.65 215d | -38.0% 131d | 2022-05-09 $296.82 | 2022-07-28 $339.92 | 60Quality on Sale | 44Watch | +18.2% 84d | +14.5% Duplicate trade Held 80d |
DROP2021-12-30$471.34 RISE2022-02-23$357.49 PEAK2022-04-07$420.45 98d | -24.2% 55d | Missed | Missed | — | — | +17.6% 43d | Missed |
DROP2021-01-08$307.53 RISE2021-03-04$257.29 PEAK2021-05-28$347.51 140d | -16.3% 55d | Missed | Missed | — | — | +35.1% 85d | Missed |
DROP2020-02-19$174.76 RISE2020-03-23$128.96 PEAK2020-05-18$218.40 89d | -26.2% 33d | Missed | Missed | — | — | +69.4% 56d | Missed |
HQY tops Q1 FY27 EPS and revenue estimates as HSA accounts and assets climb, and guidance for FY27 revenues and adjusted EPS rises.
NTRA upgrades Panorama NIPT with SNP-informed deep sequencing, validated for low fetal fraction to cut no-calls and boost reliable prenatal results.
SYK launches Pangea Plating System in Europe, completing its first London case as it broadens trauma care solutions for many fractures.
BTSG leans on surging Specialty & Infusion and integrated home health branches, but IRA and generic shifts may pressure 2026 margins.
BTSG leans on surging Specialty & Infusion and integrated home health branches, but IRA and generic shifts may pressure 2026 margins.
NTRA is expanding in Austin with what it says will be the world's largest sequencing capacity as oncology testing demand keeps surging.
NTRA is expanding in Austin with what it says will be the world's largest sequencing capacity as oncology testing demand keeps surging.
West Pharmaceutical Services has considerably outperformed the broader market over the past 52 weeks, and Wall Street analysts maintain a highly optimistic outlook about the stock’s prospects.
West Pharmaceutical Services has considerably outperformed the broader market over the past 52 weeks, and Wall Street analysts maintain a highly optimistic outlook about the stock’s prospects.
Recent performance snapshot West Pharmaceutical Services (WST) has drawn investor attention after a period of solid share performance, with the stock roughly flat over the past day but higher over the past week, month and past 3 months. At a recent close of US$316.42, West Pharmaceutical Services sits on a market value of about US$22.35b, alongside reported annual revenue of US$3.22b and net income of US$542.7m from its injectable drug packaging and delivery business. See our latest analysis...
Recent performance snapshot West Pharmaceutical Services (WST) has drawn investor attention after a period of solid share performance, with the stock roughly flat over the past day but higher over the past week, month and past 3 months. At a recent close of US$316.42, West Pharmaceutical Services sits on a market value of about US$22.35b, alongside reported annual revenue of US$3.22b and net income of US$542.7m from its injectable drug packaging and delivery business. See our latest analysis...
GEHC teams with UW Medicine Radiology to advance CT and molecular imaging, aiming to automate workflows and speed next-gen imaging to clinics.
GEHC teams with UW Medicine Radiology to advance CT and molecular imaging, aiming to automate workflows and speed next-gen imaging to clinics.
West Pharmaceutical Services (WST) passes the Minervini Trend Template with perfect moving average alignment and strong relative strength, combined with accelerating 46.9% EPS growth and 21% revenue growth, making it a high-momentum growth stock to watch.
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at West Pharmaceutical Services (NYSE:WST) and the best and worst performers in the drug development inputs & services industry.
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at West Pharmaceutical Services (NYSE:WST) and the best and worst performers in the drug development inputs & services industry.
BDX launches the Elyra Thulium Fiber Laser system to streamline kidney stone care and boost workflow flexibility for urology teams.
BDX launches the Elyra Thulium Fiber Laser system to streamline kidney stone care and boost workflow flexibility for urology teams.
INGN broadens beyond portable oxygen concentrators into home respiratory care, but U.S. revenues face pressure from channel shifts.
INGN broadens beyond portable oxygen concentrators into home respiratory care, but U.S. revenues face pressure from channel shifts.
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| WST | +7.36% | +28.48% | +17.33% | +53.10% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | +4.39% | +34.20% | +20.77% | +40.41% |
| Filed | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-14 | Campbell Shane Alden | SVP, Proprietary Segment | M Option exercise(deriv) | 474 | — | +$0 |
| 2026-05-14 | Campbell Shane Alden | SVP, Proprietary Segment | M Option exercise(deriv) | 296 | — | +$0 |
| 2026-05-14 | Campbell Shane Alden | SVP, Proprietary Segment | F Tax withholding | 135 | $312.07 | −$42.1K |
| 2026-05-14 | Campbell Shane Alden | SVP, Proprietary Segment | M Option exercise | 474 | — | — |
| 2026-05-14 | Campbell Shane Alden | SVP, Proprietary Segment | F Tax withholding | 84 | $312.07 | −$26.3K |
| 2026-05-14 | Campbell Shane Alden | SVP, Proprietary Segment | M Option exercise | 296 | — | — |
| 2026-05-06 | BUTHMAN MARK A | Director | A Grant / award | 791 | — | +$0 |
| 2026-05-06 | Feehery William F | Director | A Grant / award | 791 | — | +$0 |
| 2026-05-06 | FRIEL ROBERT F | Director | A Grant / award | 791 | — | +$0 |
| 2026-05-06 | HAUGEN JANET BRUTSCHEA | Director | A Grant / award | 791 | — | +$0 |
| 2026-05-06 | Joseph Molly | Director | A Grant / award | 791 | — | +$0 |
| 2026-05-06 | Keller Deborah L | Director | A Grant / award | 791 | — | +$0 |
| 2026-05-06 | LAI GOLDMAN MYLA | Director | A Grant / award | 791 | — | +$0 |
| 2026-05-06 | Lockhart Stephen H | Director | A Grant / award | 791 | — | +$0 |
| 2026-05-06 | Michels Douglas A | Director | A Grant / award | 791 | — | +$0 |
| 2026-05-06 | Pucci Paolo | Director | A Grant / award | 791 | — | +$0 |
| 2026-04-29 | Winters Chad | VP, Chief Accounting Officer | M Option exercise(deriv) | 896 | — | +$0 |
| 2026-04-29 | Winters Chad | VP, Chief Accounting Officer | S Open-market sale | 896 | $300.67 | −$269.4K |
| 2026-04-29 | Winters Chad | VP, Chief Accounting Officer | M Option exercise | 896 | $173.22 | +$155.2K |
| 2026-04-29 | Favorite Annette F | Sr. VP & Chief HR Officer | M Option exercise(deriv) | 2,817 | — | +$0 |
| 2026-04-29 | Favorite Annette F | Sr. VP & Chief HR Officer | S Open-market sale | 2,817 | $305.20 | −$859.8K |
| 2026-04-29 | Favorite Annette F | Sr. VP & Chief HR Officer | M Option exercise | 2,817 | $83.47 | +$235.1K |
| 2026-04-01 | HAUGEN JANET BRUTSCHEA | Director | A Grant / award(deriv) | 52 | $250.64 | +$13.0K |
| 2026-03-03 | Winters Chad | VP, Chief Accounting Officer | A Grant / award(deriv) | 808 | — | +$0 |
| 2026-03-03 | Winters Chad | VP, Chief Accounting Officer | A Grant / award(deriv) | 340 | — | +$0 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-07-23upcoming | 2.08 | — | — |
| 2026-04-23 | 1.68 | 2.13 | +27.07% |
| 2026-02-12 | 1.83 | 2.04 | +11.54% |
| 2025-10-23 | 1.67 | 1.92 | +15.14% |
| 2025-07-24 | 1.54 | 1.84 | +19.71% |
| 2025-04-24 | 1.26 | 1.45 | +15.28% |
| 2025-02-13 | 1.73 | 1.82 | +5.32% |
| 2024-10-24 | 1.46 | 1.85 | +26.92% |
| 2024-07-25 | 1.73 | 1.52 | -12.08% |
| 2024-04-25 | 1.29 | 1.56 | +21.17% |
| 2024-02-15 | 1.78 | 1.83 | +2.71% |
| 2023-10-26 | 1.86 | 2.16 | +16.20% |
| 2023-07-27 | 1.93 | 2.11 | +9.54% |
| 2023-04-27 | 1.67 | 1.98 | +18.84% |
| 2023-02-16 | 1.38 | 1.77 | +28.62% |
| 2022-10-27 | 2.12 | 2.03 | -4.25% |